ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0769 • ACR Convergence 2023

    Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort

    Austin Wheeler1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, K Wysham3, Grant Cannon4, Gary Kunkel5, Gail Kerr6, Dana Ascherman7, Paul Monach8, Andreas Reimold9, Jill Poole1, Tony Merriman10, Ted R Mikuls11 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7University of Pittsburgh, Pittsburgh, PA, 8VA Boston Healthcare System, Boston, MA, 9University of Texas Southwestern Medical Center, Dallas, TX, 10University of Alabama at Birmingham, Birmingham, AL, 11Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Although some clinical and genetic risk…
  • Abstract Number: 0808 • ACR Convergence 2023

    Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System

    Bryant England1, Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Daniel Hershberger1, Brian Sauer2, Grant Cannon3, Joshua Baker4 and Ted R Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4University of Pennsylvania, Philadelphia, PA, 5Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…
  • Abstract Number: 0976 • ACR Convergence 2023

    Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis

    Qiping Xu and Xuanling Du, Mayo Clinic Health System, Mankato, MN

    Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported…
  • Abstract Number: 1022 • ACR Convergence 2023

    Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)

    Joseph Fares1, ross Summer1 and Giorgos Loizidis2, 1The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, 2Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA

    Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
  • Abstract Number: 1260 • ACR Convergence 2023

    Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis

    Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: In recent years, numerous psychological interventions for rheumatoid arthritis (RA) patients have been developed. However, it remains unclear which psychological interventions are effective and…
  • Abstract Number: 1278 • ACR Convergence 2023

    Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability

    Manja van Wissen1, Maaike gademan1, Cornelia van den Ende2, Max Teuwen1, Wilfred Peter1, Dirkjan van Schaardenburg3, Alfons den Broeder2, Thea Vliet Vlieland4 and Salima van Weely1, 1Leiden University Medical Center, Leiden, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Reade, Amsterdam, Netherlands, 4Leids University Medical Center, Leiden, Netherlands

    Background/Purpose: Not withstanding modern treatment, some Rheumatoid Arthritis (RA) patients have severe disability due to persistently high disease activity, joint destruction/deformities and/or comorbidities. Insight into…
  • Abstract Number: 1294 • ACR Convergence 2023

    Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement

    Tim Pickles1, Mike Horton2, Karl Bang Christensen3, Rhiannon Phillips4, David Gillespie1, Neil Mo5 and Ernest Choy6, 1Cardiff University, Cardiff, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University of Copenhagen, Copenhagen, Denmark, 4Cardiff Metropolitan University, Cardiff, United Kingdom, 5Swansea Bay University Health Board, Port Talbot, United Kingdom, 6Section of Rheumatology, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Disease Activity (DA) monitoring is a standard of care in Rheumatoid Arthritis (RA). A systematic review of Patient Reported Outcome Measures (PROMs) for RA…
  • Abstract Number: 1310 • ACR Convergence 2023

    Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice

    Paola Vidal-Montal1, Alice Combier2, Alexia STEELANDT2, Marion THOMAS2, Javier Narvaez3, Joan Miquel Nolla1, Yannick ALLANORE4 and Jerome AVOUAC5, 1Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 3Hospital Universitario de Bellvitge, Barcelona, Spain, 4Université Paris Cité, Paris, France, 5Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: To compare the efficacy and tolerance at 3 and 6 months of two methotrexate (MTX) initiation strategies in rheumatoid arthritis (RA). Methods: Retrospective,monocentric,cross-sectionalstudy including…
  • Abstract Number: 1328 • ACR Convergence 2023

    Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation

    Katsuaki Onishi1, Yutaro Yamada2, Tadashi Okano2, Kenji Mamoto2, Shohei Anno3, Tatsuya Koike4 and Hiroaki Nakamura2, 1Baba Memorial Hospital, Osaka, Japan, 2Osaka Metropolitan University, Osaka, Japan, 3Yodogawa Christian Hospital, Osaka, Japan, 4Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan

    Background/Purpose: Although biologics (BIO) or Janus kinase inhibitors (JAKi) have improved treatment for rheumatoid arthritis (RA), there are patients with difficult disease activity control even…
  • Abstract Number: 1344 • ACR Convergence 2023

    Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice

    Omar AL TABAA1, Sophie HECQUET2, Marion THOMAS3, Sandrine CARVES1, Alice Combier1, Corinne MICELI4, Olivier Fogel3, Anna Molto3, Yannick ALLANORE5 and Jerome AVOUAC6, 1APHP / Cochin Hospital, Paris, France, 2APHP / Cochin Hospital / Paris University, Paris, France, 3HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 4Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 5Université Paris Cité, Paris, France, 6Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Use of JAK inhibitors (JAKi) may be challenged in difficult to treat rheumatoid arthritis (D2TRA) by the multiplicity of previous treatment lines and the…
  • Abstract Number: 1659 • ACR Convergence 2023

    Cellular Deconstruction of Stromal and Myeloid Cell Compartments in the Inflamed Synovium of Juvenile Idiopathic Arthritis

    Christopher Mahony1, Chrissy Bolton2, Charlotte Smith1, Vicky Alexiou3, Huong Nguyen3, Patricia Reis-Nisa1, Søren Lomholt4, Annie Hackland1, Sunit Davda5, Sugrah Sultan6, Charlene Foley5, Catherine Cotter6, Klaudia Kupiec3, Calliope Dendrou2, Elizabeth C Rosser7, Accelerating Medicines Partnership (AMP): RA/SLE8, Fan Zhang9, Soumya Raychaudhuri8, Michael Brenner10, Christopher Buckley2, Manigandan Thyagarajan6, Accelerating Medicines Partnership Program RA SLE Network11, Zishan Shiekh6, Sandrine Compeyrot-Lacassagne5, Samantha Chippington5, Mark Coles2, Eslam Al-Abadi6, Andrew Filer1, Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium12, Lucy R Wedderburn3 and Adam Croft1, 1University of Birmingham, Birmingham, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3UCL Great Ormond Street Institute of Child Health, London, United Kingdom, 4Aarhus University, Aarhus, Denmark, 5Great Ormond Street Hospital, London, United Kingdom, 6Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, 7University College London, London, United Kingdom, 8Brigham and Women's Hospital, Boston, MA, 9University of Colorado, Aurora, CO, 10Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12MRC, Birmingham, United Kingdom

    Background/Purpose: The synovial membrane is the primary target tissue during the effector phase of inflammatory arthritis in children and young people with Juvenile Idiopathic Arthritis…
  • Abstract Number: 1729 • ACR Convergence 2023

    An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases

    Yuhao Qin1, Wenming Ren2, Liangqin Tong3, lu su3 and cheng liao3, 1Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China, 2Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pudong New District, China, 3Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

    Background/Purpose: Tumor necrosis factor α (TNFα) is a pivotal pro-inflammatory cytokine. And TNF inhibitors are the most successful anti-rheumatic drugs for the treatment of autoimmune…
  • Abstract Number: 1745 • ACR Convergence 2023

    Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo

    Corinna Heck1, Sophie Haun1, Daria Kürsammer1, Klaus Frommer1, Mona Arnold1, Markus Rickert2, Katrin Susanne Lips3, Stefan Rehart4, Ulf Müller-Ladner1 and Elena Neumann1, 1Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 2Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, 3Justus Liebig University Gießen, Department of Experimental Trauma Surgery, Giessen, Germany, 4Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany

    Background/Purpose: In the inflamed synovium of RA patients, increased and altered angiogenesis is a pathological feature. Key players are chronically activated RA synovial fibroblasts (RASF),…
  • Abstract Number: 1761 • ACR Convergence 2023

    JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis

    Lidia La Barbera1, Marianna Lo Pizzo1, Chiara Rizzo1, Leila Mohammadnezhad1, federica Camarda1, Francesco Ciccia2 and Giuliana Guggino1, 1University of Palermo, Palermo, Italy, 2University of Campania - Luigi Vanvitelli, Naples, Italy

    Background/Purpose: Recent evidence suggests that innate lymphoid cells (ILCs) might be involved in rheumatoid arthritis (RA) pathogenesis and individuals at risk of RA exhibited an…
  • Abstract Number: 1821 • ACR Convergence 2023

    The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage

    Shobhit Piplani1, Shreya Gulati2, Vladimir Jelic1, Asad Ahmed3, Sung Mi Yoon1, Donclair Brown1, Miroslav Radulovic1 and Beverly Johnson4, 1Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine, NYC Health and Hospitals, Bronx, NY, 2Jawahar lal Nehru Medical College, New York, NY, 3SUNY Downstate, Brooklyn, NY, 4Albert Einstein College of Medicine, Jacobi/NCB, New York, NY

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication commonly associated with autoimmune disorders. Limited treatment options are available for DAH, and time to…
  • « Previous Page
  • 1
  • …
  • 70
  • 71
  • 72
  • 73
  • 74
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology